Loading page…

Orchid Pharma Limited (ORCHPHARMA) · mywealthgrid

Orchid Pharma Limited

NSE:ORCHPHARMA BSE:ORCHPHARMA

HealthcarePharmaceuticals & Biotechnology

₹990.0

-0.7%1 Oct close

Mkt cap

₹5,019 Cr

Watch Alert Compare

About

Orchid Pharma Limited operates in Pharmaceuticals & Biotechnology within the Healthcare sector. With a market cap of ₹5,301 Cr, it posted quarterly revenues of ₹173–₹238 Cr (Jun 2025 to Mar 2026), though quarterly profitability has been highly inconsistent.

Face value: ₹10

Market cap

₹5,019 Cr

P/E

467.8×

P/B

3.2×

Dividend yield

ROE

0.7%

ROCE

1.7%

Debt / equity

0.19

OPM

2.7%

EPS (TTM)

₹2.1

Book value

₹308.5

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Net profit volatility: swung from +₹30.6 Cr to -₹12.61 Cr across recent quarters, raising questions about operational control and business stability.

Valuation disconnect: PE of 260.39 and ROE of 1.61% suggest the stock is priced for significant improvement; verify what operational or market catalyst is expected.

Margin instability: operating margins ranged from -0.76% to +12.2% quarter-to-quarter; verify whether this reflects product mix, cost control, pricing, or one-time items.

No shareholder returns: no dividends since 2012, and current low profitability makes future payouts uncertain.

Generated analysis · source review pending

Growth drivers

Revenue grew 37% over three quarters from ₹173 Cr (Jun 2025) to ₹238 Cr (Mar 2026).

Mar 2026 net profit of ₹30.6 Cr and operating margin of 12.2% were highest in recent quarters; verify if this level is repeatable and what drove the improvement.

Low leverage (D/E 0.28) provides balance-sheet capacity for reinvestment or growth; verify management's capital allocation strategy.

Pharma sector in India has structural growth drivers; verify Orchid's competitive position, product portfolio, and addressable market opportunities.

Generated analysis · source review pending

1,457 historical price candles were omitted because the exchange source has not been verified.

₹990.0-2.5%1Y

Quick read

rule-based

Pros

+Revenue CAGR of 22.3% over the last 5 years
+High promoter holding of 69.8% with no pledge

Cons

−Low return on equity of 6.3% (3-yr avg)
−Thin operating margin of 2.7%
−Profit declined 40.1% a year over the last 3 years
−Expensive at 467.8× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

30/100

Business quality: 21
Growth: 48
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	450	560	666	819	922	1,233
COGS	229	314	385	484	544	844
Gross profit	222	246	281	335	378	388
	172	196	200	227	257	355
	50	50	81	108	121	33
OPM %	11.1%	8.9%	12.2%	13.2%	13.1%	2.7%
Depreciation	109	87	55	33	35	43
Interest	51	32	32	16	15	9
	-6	67	52	31	27	29
Profit before tax	-117	-2	46	89	99	10
Tax	0	0	0	-3	-0	-0
Tax %	0%	0%	0%	-3.5%	-0.2%	-1.9%
	-117	-2	46	92	100	10
PAT margin %	-25.9%	-0.4%	7%	11.3%	10.8%	0.8%
EPS (₹)	-28.6	-0.5	11.4	19.1	19.7	1.7
EPS adjusted (₹)	-28.6	-0.5	11.4	18.2	19.7	1.7
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	89	89	41	41	41	41	51	51	60
Reserves	-881	-793	725	612	607	648	1,119	1,217	1,504
	1,894	2,120	507	453	268	331	134	174	301
	2,023	1,661	187	132	195	205	250	246	393
Total equity & liabilities	3,125	3,077	1,460	1,237	1,111	1,225	1,554	1,688	2,258
	1,386	1,256	858	670	584	573	620	633	687
CWIP	257	264	15	7	10	46	16	64	341
Investments	1	0	15	15	46	44	46	50	67
	1,481	1,556	572	544	471	561	872	941	1,164
Total assets	3,125	3,077	1,460	1,237	1,111	1,225	1,554	1,688	2,258

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	49.2%	44%	42.2%	40.9%	41%	31.5%
EBITDA margin %	11.1%	8.9%	12.6%	13.5%	12.7%	2.7%
EBIT margin %	-13.1%	-6.7%	4.3%	9.4%	9%	-0.8%
PAT margin %	-25.9%	-0.4%	7%	11.3%	10.8%	0.8%
Working capital
Receivable days	110	111	118	87	96	113
Inventory days	244	201	217	199	219	161
Payable days	176	195	173	173	149	150
NWC days	179	117	163	113	166	124
Leverage
Current ratio	3.87	1.87	1.35	3.04	2.83	1.89
Debt to EBITDA	9.09	5.4	3.96	1.22	1.49	8.98
Debt to equity	0.69	0.41	0.48	0.11	0.14	0.19
Interest coverage	-0.9	-0.9	1.5	6.6	7.6	3
Asset turnover	0.36	0.5	0.54	0.53	0.55	0.55
Return ratios
Return on assets %	-9.4%	-0.2%	3.8%	5.9%	5.9%	0.4%
Return on capital employed %	-4%	-2.9%	5.6%	10.1%	8.2%	1.7%
Return on equity %	-17.8%	-0.3%	6.7%	7.9%	7.9%	0.6%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	72.4%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%	69.84%
	8.08%	4.14%	1.96%	1.42%	1.94%	2.53%	2.69%	1.4%	1.56%	1.17%	0.87%	0.81%
	12.47%	14.5%	17.73%	18.93%	18.29%	18.99%	20.1%	19.43%	19.04%	19.39%	20.25%	20.75%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	7.05%	11.52%	10.47%	9.81%	9.93%	8.64%	7.37%	9.33%	9.56%	9.6%	9.04%	8.6%
No. of shareholders	—	—	—	—	—	—	—	—	38,155	35,709	35,118	33,433

Promoter holding down 2.56 percentage points since Sep 2023.

3 deals · 28 Nov 2023 – 30 May 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
30 May 2025	UTI MUTUAL FUND	Bulk	NSE	Buy	3,66,507	₹615.37	₹22.55 Cr
28 Nov 2023	DHANUKA LABORATORIES LIMITED	Bulk	BSE	Sell	13,00,000	₹571.28	₹74.27 Cr
28 Nov 2023	UTI MUTUAL FUND	Bulk	BSE	Buy	4,45,000	₹571.00	₹25.41 Cr

1–3 of 3

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Ram Gopal AgarwalNon-Executive - Non Independent Director-Chairperson
Mr. Manish DhanukaExecutive Director-MD
Mr. Mridul DhanukaExecutive Director
Mr. Arjun DhanukaNon-Executive - Non Independent Director
Mr. Dharam VirNon-Executive - Independent Director
Mr. Manoj Kumar GoyalNon-Executive - Independent Director
Ms. Shubha SinghNon-Executive - Independent Director
Ms. Tanu SinglaNon-Executive - Independent Director
Mr. Sunil Kumar GuptaChief Financial Officer
Mr. Kapil DayyaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 3 fund houses

Held by these funds

4.94%

of the company's equity

All mutual funds

19.93%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

9 schemes · 3 fund houses

		Shares
Portfolio of Kotak Multi Asset Allocation Fund	Kotak Mahindra Mutual Fund	9.43 L	91.55	0.6%	1.86%	-0
Portfolio of Kotak Special Opportunities Fund	Kotak Mahindra Mutual Fund	4.78 L	46.39	2.72%	0.942%	+50,000
Portfolio of Kotak Consumption Fund	Kotak Mahindra Mutual Fund	2.86 L	27.77	1.6%	0.564%	-0
Portfolio of Kotak Multi Cap FundNEW	Kotak Mahindra Mutual Fund	2.64 L	25.66	0.08%	0.521%	—
Portfolio of Kotak MNC Fund	Kotak Mahindra Mutual Fund	2.6 L	25.24	1.09%	0.513%	-0
INDIA INNOVATION FUND	Tata Mutual Fund	1.44 L	13.99	1.04%	0.284%	-0
Portfolio of Kotak Healthcare Fund	Kotak Mahindra Mutual Fund	1.3 L	12.62	1.64%	0.256%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	417	0.04	0.09%	0.001%	-0

1–8 of 9

1 / 2

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Aug 2026Transcript AI Summary PPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

6

Dividend dividend13 Sept 2012 · ex-date₹3
Dividend dividend19 Jul 2011 · ex-date₹3
Dividend dividend12 Jul 2010 · ex-date₹10
Dividend dividend17 Sept 2009 · ex-date₹1
Dividend dividend18 Sept 2008 · ex-date₹3
Dividend dividend12 Jul 2007 · ex-date₹3

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

29 announcementsExport CSV

29 Sept 2026, 6:42 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	49.2%	44%	42.2%	40.9%	41%	31.5%
EBITDA margin %	11.1%	8.9%	12.6%	13.5%	12.7%	2.7%
EBIT margin %	-13.1%	-6.7%	4.3%	9.4%	9%	-0.8%
PAT margin %	-25.9%	-0.4%	7%	11.3%	10.8%	0.8%
Working capital
Receivable days	110	111	118	87	96	113
Inventory days	244	201	217	199	219	161
Payable days	176	195	173	173	149	150
NWC days	179	117	163	113	166	124
Leverage
Current ratio	3.87	1.87	1.35	3.04	2.83	1.89
Debt to EBITDA	9.09	5.4	3.96	1.22	1.49	8.98
Debt to equity	0.69	0.41	0.48	0.11	0.14	0.19
Interest coverage	-0.9	-0.9	1.5	6.6	7.6	3
Asset turnover	0.36	0.5	0.54	0.53	0.55	0.55
Return ratios
Return on assets %	-9.4%	-0.2%	3.8%	5.9%	5.9%	0.4%
Return on capital employed %	-4%	-2.9%	5.6%	10.1%	8.2%	1.7%
Return on equity %	-17.8%	-0.3%	6.7%	7.9%	7.9%	0.6%

Date	Category	Subject	Filing
29 Sept 2026, 6:42 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
28 Sept 2026, 6:29 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
22 Sept 2026, 9:22 pm	Company Update General	Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirement Regulations), 2015	PDF
21 Sept 2026, 6:10 pm	Company Update General	Investor Roadshow Scheduled To Be Held In Mumbai	PDF
8 Sept 2026, 8:35 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
8 Sept 2026, 4:02 pm	Others Business Responsibility and Sustainability Reporting (BRSR)	Business Responsibility and Sustainability Reporting (BRSR)	PDF
7 Sept 2026, 11:57 pm	AGM/EGM AGM	Notice Of 33Rd Annual General Meeting Of Orchid Pharma Limited ('The Company') For The F.Y. 2025-26	PDF
3 Sept 2026, 8:29 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management	PDF

₹ Cr	Mar 2016	Mar 2017	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	212	317	29	89	19	126	19	126
	-1	-9	95	116	-31	-312	-27	-277
	-286	-366	85	-217	31	167	25	137
Net cash flow	-76	-58	209	-11	18	-19	18	-14
Free cash flow	211	309	28	75	-66	61	-131	-264
CFO / Operating profit %	—	—	58.1%	179.3%	22.2%	113.8%	16.4%	374.3%

Orchid Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

6

1

Announcements

6

1

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Orchid Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends6

Board meetings1

Announcements

Dividends6

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

6

1

6

1